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CARDIOMETABOLIC RISKSTATE-OF-THE-ART PAPERSVascular Function and Diabetes 667
Dimitris Tousoulis, Nikolaos Papageorgiou, Emmanuel Androulakis, Gerasimos Siasos,
George Latsios, Konstantinos Tentolouris, Christodoulos Stefanadis
Diabetes mellitus (DM) impairs endothelial nitric oxide synthase activity, enhances the
production of reactive oxygen species, and leads to other pro-atherogenetic alterations.
Tousoulis and colleagues review the utility of serum biomarkers as markers of vascular risk
and as guides to effective therapy. Several biomarkers are potentially useful; these include
markers of endothelial function, inﬂammation, coagulation processes, and oxidative stress.
These biomarkers could explain the different pathophysiological aspects in patients with DM
and may serve as useful surrogate markers of reduced cardiac risk.STATE-OF-THE-ART PAPERSCardiometabolic Risks of Gestational Diabetes 677
Shireen Brewster, Bernard Zinman, Ravi Retnakaran, John S. Floras
Gestational diabetes, and even milder forms of dysglycemia during pregnancy, represent a
maternal phenotype at increased risk of developing type 2 diabetes mellitus, metabolic
syndrome, and, eventually, overt cardiovascular disease. Brewster and colleagues review the
magnitude of such risk and its potential causes, with a particular focus on alterations
post-partum in endothelial and vascular smooth muscle responsiveness. Understanding the
hormonal, metabolic, and vascular changes occurring in such women provides a unique
opportunity to identify conventional and novel conditions and biomarkers of later
cardiovascular risk.CLINICAL RESEARCH OBESITY AND PERCUTANEOUS INTERVENTIONThe Epidemic of Obesity in PCI Patients 685Michael E. Buschur, Dean Smith, David Share, William Campbell, Stephen Mattichak,
Manoj Sharma, Hitinder S. Gurm
Buschur and colleagues reviewed data from a large database to examine the prevalence and
clinical implications of morbid obesity (body mass index [BMI] >40 kg/m2) among patients
undergoing percutaneous coronary intervention (PCI). The proportion of morbidly obese
patients increased from 4.4% in 1998 to 8.4% in 2009. Compared with overweight patients
(BMI 25 to 30 kg/m2), these patients had signiﬁcantly increased vascular complications,
contrast-induced nephropathy, nephropathy requiring dialysis, and mortality. These results
have important implications for technical considerations of cardiac catheterization and the
design of the catheterization laboratory to accommodate morbidly obese patients.(continued on page A-22)
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Saeed Payvar, Sunghee Kim, Sunil V. Rao, Ronald Krone, Megan Neely, Nikhil Paladugu,
Ramesh Daggubati
Payvar and colleagues analyzed CathPCI Registry data to compare in-hospital outcomes of
percutaneous coronary intervention in patients with extreme obesity (EO) (body mass
index 40 kg/m2) with that of normal weight (NW) patients. Compared with NW patients,
EO patients were younger, more likely female, and more often African American. EO
patients had lower unadjusted mortality; however, after multivariable adjustment, in those
presenting with ST-segment elevation myocardial infarction, EO was independently
associated with increased risk of in-hospital mortality (odds ratio: 1.22).METABOLIC SYNDROMEU.S. Trends in Metabolic Syndrome, 1999–2010 697
Hiram Beltrán-Sánchez, Michael O. Harhay, Meera M. Harhay, Sean McElligott
Beltrán-Sánchez and colleagues used National Health and Nutritition Examination Survey
(NHANES) data to characterize the prevalence of metabolic syndrome (MetS), its 5
components, and their pharmacological treatment in U.S. adults over the last 20 years. From
1999 to 2000 to 2009 to 2010, the age-adjusted prevalence of MetS (based on biologic
thresholds) decreased from 25% to 23%. During this period, hypertriglyceridemia and
elevated blood pressure prevalence decreased, while the prevalence of hyperglycemia and
elevated waist circumference increased. These trends varied considerably by gender and race/
ethnicity groups. Decreases in elevated blood pressure, suboptimal triglycerides, and high-
density lipoprotein cholesterol prevalence were likely due to an increased use of
antihypertensive and lipid-modifying drugs.(continued on page A-24)
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Suzanne V. Arnold, Kasia J. Lipska, Yan Li, Abhinav Goyal, Thomas M. Maddox,
Darren K. McGuire, John A. Spertus, Mikhail Kosiborod
The factors that comprise the metabolic syndrome (MetS) are believed to be altered in the
setting of an acute myocardial infarction (AMI), potentially limiting its prognostic
signiﬁcance. Arnold and colleagues assessed MetS metabolic factors in patients presenting
with acute myocardial infarction (AMI) and 1 month later. A total of 69% of the patients
hospitalized for AMI met the diagnostic criteria for MetS during the hospitalization and 63%
did at 1 month. Inpatient MetS diagnosis had a sensitivity and speciﬁcity for outpatient
diagnosis of 87% and 61%, respectively. Patients with MetS at either time point had worse
outcomes. MetS can be reliably diagnosed during the initial hospitalization for AMI and
identiﬁes patients at higher risk for poor outcomes.STATIN TREATMENTStatins and Exercise Training Adaptations 709
Catherine R. Mikus, Leryn J. Boyle, Sarah J. Borengasser, Douglas J. Oberlin, Scott P. Naples,
Justin Fletcher, Grace M. Meers, Meghan Ruebel, M. Harold Laughlin, Kevin C. Dellsperger,
Paul J. Fadel, John P. Thyfault
Mikus and associates examined the effects of simvastatin on cardiorespiratory ﬁtness and
skeletal muscle mitochondrial content in response to aerobic exercise training. Sedentary
overweight or obese adults were randomized to 12 weeks of aerobic exercise training or to
exercise in combination with simvastatin (40 mg/day). Cardiorespiratory ﬁtness and skeletal
muscle synthase activity increased with exercise alone, but no beneﬁts were seen in the
patients simultaneously taking simvastatin. Simvastatin attenuates the beneﬁcial increases in
cardiorespiratory ﬁtness and skeletal muscle mitochondrial content seen with exercise
training.
Editorial Comment: Paul D. Thompson, Beth Parker, p. 715(continued on page A-25)
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Peter S. Sever, Neil R. Poulter, Choon L. Chang, Simon A. M. Thom, Alun D. Hughes,
Paul Welsh, Naveed Sattar, on behalf of the ASCOT Investigators
Sever and colleagues investigated the relationship of baseline and on-treatment C-reactive
protein (CRP) levels with subsequent cardiovascular events using a subset of primary
prevention subjects enrolled in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).
Subjects were randomized to 10 mg of atorvastatin or placebo. The risk of subsequent events
increased with baseline CRP, but the relative beneﬁt of atorvastatin in preventing
cardiovascular events did not differ according to baseline CRP. After 6 months, subjects who
achieved low-density lipoprotein cholesterol (LDL-C) below the median, had a reduced
cardiovascular risk compared with those who did not, but in contrast those who achieved a
CRP level below the median did not have a reduced risk. These results show that statin
dosage should be titrated to LDL-C levels regardless of the CRP levels.
Editorial Comment: Roger S. Blumenthal, Chiadi E. Ndumele, Seth S. Martin, p. 730QUANTIFYING CARDIOMETABOLIC RISKEstimated Versus Direct Measured LDL-C 732
Seth S. Martin, Michael J. Blaha, Mohamed B. Elshazly, Eliot A. Brinton, Peter P. Toth,
John W. McEvoy, Parag H. Joshi, Krishnaji R. Kulkarni, Patrick D. Mize,
Peter O. Kwiterovich, Andrew P. DeFilippis, Roger S. Blumenthal, Steven R. Jones
Martin and colleagues compared Friedewald-estimated and directly measured low-density
lipoprotein cholesterol (LDL-C) values. Over 1 million U.S. adults underwent lipid proﬁling
by vertical spin density gradient ultracentrifugation and had triglycerides <400 mg/dl.
Greater differences in Friedewald versus direct LDL-C occurred at lower LDL-C and higher
triglyceride levels. If Friedewald-estimated LDL-C was <70 mg/dl, median direct LDL-C
was 9.0 mg/dl higher when triglycerides were 150 to 199 mg/dl and 18.4 mg/dl higher when
triglycerides were 200 to 399 mg/dl. Of patients with Friedewald LDL-C <70 mg/dl, 39%
had a direct LDL-C 70 mg/dl if triglycerides were 150 to 199 mg/dl and 59% if
triglycerides were 200 to 399 mg/dl. The Friedewald equation tends to underestimate
LDL-C especially if triglycerides are 150 mg/dl.
Editorial Comment: John C. LaRosa, p. 740(continued on page A-26)
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Michael Khoury, Cedric Manlhiot, Brian W. McCrindle
Body mass index (BMI) is a commonly used indirect indicator of adiposity and
cardiometabolic risk in children. The waist-to-height ratio (WHtR), a marker of central
adiposity, may be more useful. National Health and Nutrition Examination Survey
(NHANES) data were reviewed for almost 15,000 children age 5 to 18 years. Overweight
and obese subjects with a WHtR <0.5 had a cardiometabolic risk similar to subjects with a
normal BMI. Obese subjects with WHtR 0.6, frequently had elevated non–high-density
lipoprotein levels, elevated C-reactive protein (CRP), and insulin resistance. These results
suggest that the WHtR can be used to identify children with high BMIs who should undergo
a further cardiometabolic risk assessment.ADIPOSE DISTRIBUTIONNatriuretic Peptides and Fat Distribution 752Ian J. Neeland, Benjamin R. Winders, Colby R. Ayers, Sandeep R. Das, Alice Y. Chang,
Jarett D. Berry, Amit Khera, Darren K. McGuire, Gloria L. Vega, James A. de Lemos,
Aslan T. Turer
Natriuretic peptides stimulate lipolysis, reduce weight gain, and promote adipocyte browning
in animal models but data are lacking in humans. A total of 2,619 participants without heart
failure in the Dallas Heart Study underwent measurements of: 1) B-type natriuretic peptide
(BNP) and N-terminal pro–B-type natriuretic peptide (NT-proBNP); and 2) body fat
distribution by dual energy x-ray absorptiometry and magnetic resonance imaging. In
multivariable analyses, NT-proBNP remained inversely associated with visceral and liver fat
and positively associated with lower body fat independent of age, sex, race, and obesity status.
These results suggest that increased cardiomyocyte production of natriuretic peptides can
improve adipose tissue distribution.
Editorial Comment: Jan Westerink, Wilko Spiering, p. 761
